Complix

company

About

Complix is a biopharmaceutical company developing Alphabodies, a novel class of biopharmaceuticals.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
€12M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€12M $6.20M
Complix has raised a total of €12M $6.20M in funding over 2 rounds. Their latest funding was raised on Jun 26, 2013 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 26, 2013 Series B €12M 3 Detail
Jun 10, 2010 Series A $6.20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
4
Complix is funded by 4 investors. Baekeland Funds and Vinnof are the most recent investors.
Investor Name Lead Investor Funding Round
Baekeland Funds Series B
Vinnof Series B
TrustCapital Series B
CRP Sante Series A